← Back to Clinical Trials
Recruiting Phase 2 NCT04899687

Study of Dextromethorphan in OCD and Related Disorders

Trial Parameters

Condition Obsessive-Compulsive Disorder
Sponsor Stanford University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2022-01-20
Completion 2026-04-01
Interventions
FluoxetineDextromethorphan

Brief Summary

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD) * Living within California * Capacity to provide informed consent Exclusion Criteria: * Current bipolar disorder or psychotic disorder * Active moderate or severe substance use disorder, lifetime severe substance use disorder * Pregnant or nursing women * Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start * Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start

Related Trials